🔗 Share this article

As America undertakes unprecedented revisions to its vaccination guidelines, one figure has surfaced somewhat surprisingly: Høeg, an American of Danish descent sports medicine doctor and public health researcher who initially gained attention by expressing skepticism about coronavirus vaccinations in the pandemic and has concentrated on potential fatalities following Covid vaccination in her recent position at the US Food and Drug Administration (FDA).

Planned Overhauls to Pediatric Immunization Program

Health officials were set to unveil major revisions to the pediatric vaccine schedule recently, synchronizing the US with Denmark’s national calendar, it is understood – a substantial departure that would place the US out of step with much of the international standard with little proof for improved outcomes. The planned update has been postponed until the new year.

In place of the top vaccines chief, Høeg is listed to address the audience at the event. She was newly appointed acting director of the FDA’s drug evaluation center, the fifth individual to run the center this calendar year.

A Shift at the Regulatory Body

This interim role may indicate a strengthened alliance between the drug and biologics branches as Høeg and Prasad solidify control at the agency – and it suggests a increased emphasis upon rolling back previously authorized vaccines at the FDA.

The new acting director has frequently advocated for discontinuing some pediatric immunization guidelines in the US so as to align more like the Danish model, a society with universal health coverage and a population about the size of Wisconsin’s.

So far public appearances, she has kept her attention on vaccines – traditionally the responsibility of Dr. Prasad, head of the FDA’s vaccine center – rather than medication approval.

Concerns Over Background

Høeg has little discernible track record in pharmaceutical research, approval processes or administrative roles, which has been standard for past leaders of the CBER. She has been employed at the FDA as a top consultant to the commissioner and the vaccine center since earlier this year.

“It seems she lacks to have any of the qualifications” for leading the CDER, said a neurologist and psychiatrist. “She’s never run a randomized controlled trial. She lacks experience in leading a large organization. She has no expertise in industry regulation.”

Previous commissioners of CBER would “be deeply familiar with laws and regulations and the underlying principles of pharmaceutical innovation”, noted Janet Woodcock. “Clearly, she lacks the kind of background that prior appointees who ran the center have had.”

This division has an enormous workload at the FDA, Woodcock stated.

“Many people just focuses on the novel medication approvals, but the generic drug division authorizes thousands of off-brand pharmaceuticals. There is also a biosimilars division, over-the-counter program and more, and each of these must be managed,” Dr. Woodcock said. “The responsibility you don’t keep your eye on, that’s the thing that I always told people is going to bite you.”

Additionally, a substantial administrative element to the role, which supervises over 5,000 employees. “It’s a enormous management job, if you execute it properly,” the former official concluded.

Response and Contentious Policies

When asked about questions about Høeg’s credentials and whether this appointment indicates greater collaboration among regulatory chiefs on vaccines, a press secretary stated that the “concerns are based on incorrect assumptions”.

“Her resume aligns with the functions of her job,” the spokesperson explained, pointing to the period Dr. Høeg spent advising the agency head on “pharmaceutical safety and regulatory science, including computational safety modeling and immunization monitoring”.

As acting director, Dr. Høeg assumes responsibility for the agency head's recently launched expedited review system, a controversial expedited medication authorization process that reportedly troubled her preceding directors. “How are these therapies being picked for this fast-track system? Who makes the choices?” Dr. Howard questioned. “There is a lot of secrecy going on at the agency right now.”

In general, he stated, “the Food and Drug Administration appears to be shifting towards less stringent regulations of most medications, aside from immunizations.”

Established Past Work on Vaccines

Regarding immunizations, Dr. Høeg has a clearer, if troubling, history, critics said. She released a study using unconfirmed crowd-sourced reports to estimate the rate of heart inflammation after Covid immunization. She counseled the state of Florida chief medical officer Dr. Joseph Ladapo, who reportedly have altered data to imply Covid vaccinations are pose a greater threat than they are.

Among her “policy goals” for the new government included changing rules for recently developed shots and ending “unnecessary” immunizations, she remarked after the election on a podcast. At the agency, Høeg has reportedly proposed preventing teenage boys from obtaining Covid vaccines.

“She is an all-around dogmatist who begins with her beliefs and works backwards to retrofit the data in a very disingenuous, untruthful fashion,” Howard stated.

Gaining Influence and a “Campaign of Retribution”

Høeg aligned with other contrarians, {like|